Share this page:

Exclusive video lecture series in biosimilar development

Watch for free the presentations from the 2nd Biosimilars Forum

Sign up and watch the lectures delivered at the 2nd Biosimilars Forum by the World’s prominent experts of this complex drug development field.

The 1st and 2nd lessons of the 3-part course about the 'Open issues in the assessment of bioequivalence and biosimilarity' lectured by Helmut SCHÜTZ (Owner at BEBAC – Consultancy Services) are available now.

Start to learn from leading biosimilar research experts! The lecture videos of the series provide a detailed overview about actual issues and challenges of follow-on biologics and guidance for their handling. It is essential for research management, leadership and support teams working across biosimilar drug development.

   Multi-Group and Multi-Site Studies. To pool or not to pool?  | Available now

Please, fill out the sign-up form100% free. Sign up in 30 seconds and get free access to this essential video lecture series in biosimilar development.

The full-length presentation videos of the series include the professional courses and lectures delivered during the 2nd Biosimilars Forum by leading experts in biosimilar development (webcasting stream recorded on 5-6 OCT, 2017).

  • This lecture series with high-quality video courses and presentations provide:
    • a deep insight into the statistical and regulatory aspects of biosimilar research
    • recent scientific and practical knowledge on the assessment of biosimilar products
    • with an open discussion about recent development challenges of biosimilars and guidance for their handling
  • Delivered by leading biosimilar development experts from around the world:
    • regulatory professionals
    • medical scientists, academicians
    • biostatisticians
    • clinical researchers
    • pharmaceutical developers
Get your free access to the video lectures

How does it work?
The 1st and 2nd video lessons are available now. Sign up by filling out this form and we will email you access for this presentation streams within 1 business day. Each videos of the series will arrive every 2 weeks. The organizers of the Biosimilars Forum will notify you by email when the following presentation is available to watch:

Share this page:

LIST OF VIDEO LECTURES OF THE SERIES

3-part course: Open issues in the assessment of bioequivalence and biosimilarity

 Available NOW |    53:37

1st Lesson of the course:

Unequal carry-over - “solved” in BE but still an Issue in assessing biosimilarity?

 Available NOW |    52:05

2nd Lesson of the course:

Multi-Group and Multi-Site Studies. To pool or not to pool?

 Coming: End of MAY |  1:39:40

3rd Lesson of the course (with 2 topics):

Group-Sequential and Two-Stage Designs / Reference-scaling and Control of the Type I Error

lectured by Helmut SCHÜTZ
Owner at BEBAC – Consultancy Services for Bioequivalence and Bioavailability Studies

 Coming: Early JUN |    33:25

Clinical trials for biosimilars in Europe: an updated systematic comparison of the clinical development programs

Johanna MIELKE
Biostatistician,
Novartis Pharma AG

 Coming: Mid JUN |    1:04:35

Scientific factors in biosimilar product development

László ENDRÉNYI
Professor Emeritus of Pharmacology and Biostatistics, University of Toronto; Former President of Canadian Society for Pharmaceutical Scientists

 Coming: Early JUL |    32:45

Algorithms for evaluating reference scaled average bioequivalence: power, bias and consumer risk

László TÓTHFALUSI
Associate Professor, Faculty of Pharmacology, Semmelweis University / Co-Author: László ENDRÉNYI, Prof. Emeritus of University of Toronto

 Coming: Mid JUL  |    26:30

Regulatory perspective on comparison of quality attributes in drug development

Ina-Christine RONDAK
Biostatistician, Seconded National Expert from Klinikum rechts der Isar of Technische Universität München to EMA

 Coming: Early AUG |    51:02

Keynote Presentation: Nanosimilar development:

Immune side effects of biologicals and nanomedicines: unsolved issues in bio- and nanosimilar development

János SZEBENI
Director of the Nanomedicine Research and Education Center, Semmelweis Medical University

 100% FREE!

Don't miss this special opportunity!

Sign up in 30 seconds and get an access to this essential video lecture series in biosimilar development.


Click here to read our detailed Terms and Privacy policy
TERMS & PRIVACY POLICY

This policy is written in order to inform you about the following subjects:

    • We request some data from you during application for the relevant service available on our website, however we do not collect any data in addition to those to be filled in the forms.
    • Upon subscribing to our lecture series, you will receive information about the event, publicity materials and surveys.
    • We use cookies to generate aggregated, anonymous statistics.
    • All of your data is safe with us, we do not disclose it to any third party in any form. Ever.

 

Legally speaking:

The Annual Biosimilars Forum event series is organized by two prestigious Central European scientific societies, the Viennese Section of the IBS and the Hungarian Society for Clinical Biostatistics in cooperation with the Accelsiors CRO Ltd. (hereinafter jointly referred to as: “Organizers”). On behalf of the Organizers the marketing activity of the event is handled by Accelsiors CRO Ltd. (1147 Budapest, Miskolci utca 50., Hungary). The conditions of use of this website and principles of data privacy are subject to Hungarian law.

In accordance with the provisions of Act CXII of 2011 on Informational Self-Determination and Freedom of Information, Act XLVIII of 2008 on the Basic Requirements and Certain Restrictions of Commercial Advertising Activities, Act CVIII of 2001 on Certain Issues of Electronic Commerce Activities and Information Society Services, as well as other applicable legal regulations, Accelsiors Ltd. on behalf of the organizers of Annual Biosimilars Forum event series (hereinafter jointly referred to as: “Annual Biosimilars Forum”), hereby disclose their data protection and data management principles in the form of this Statement. Annual Biosimilars Forum shall handle such data only as has been voluntarily provided by the data subjects, and shall have their prior written consent for handling.

Annual Biosimilars Forum request data from the users of its services during application for the relevant service available on its Web Site at www.biosimsforum.com.

During the registration process, Annual Biosimilars Forum does not collect or otherwise acquire any data in addition to those to be filled in the forms. Simultaneously with their registration Users agree to the processing of their registration data. During data processing Annual Biosimilars Forum uses the provided personal data, in addition to the performance of the selected service, exclusively for market research activities and offers.

Annual Biosimilars Forum uses the data collected during the registration process exclusively for the purposes there specified and does not add it to its databases from other sources. Annual Biosimilars Forum does not disclose the data collected during the registration process to any third party in any form.

The Organizers reserve the right to not share this videos without prior notice. In case of sign-up rejection the organizers will delete all the personal data recorded at the sign-up form by the subscriber immediately.

Annual Biosimilars Forum places cookies in the Users’ computers who complete the registration, for the purpose of facilitating the Users’ subsequent log-in. Accepting the cookies does not provide Annual Biosimilars Forum access to the computer of the User or the User’s personal information other than which the User decides to disclose. This policy is strictly adhered to by Annual Biosimilars Forum. The visitor can decide whether to accept the cookies. If the visitor does not wish to accept the use of cookies, they can set their browser to send a warning about the request for the placement of cookies, or to automatically disallow cookies.

Annual Biosimilars Forum will take every reasonable effort to maintain the confidentiality of the acquired data and to comply with the data protection requirements; however, Annual Biosimilars Forum cannot assume any responsibility for the disclosure of any data due to the potential occurrence of any vis major event.

Visitors may subscribe to the video lecture series newsletter of Annual Biosimilars Forum on its website, which requires the provision of personal data (first name and email address) on the site. The Organizers shall manage and use the personal data provided by data subjects only until the latter revoke their authorisation for data processing, shall use them only for the realization of the objectives provided below, and only to the extent required for these objectives:

  • to provide information on the programme of Annual Biosimilars Forum, as well as relevant facts about individual events (e.g. change of date, cancellation);
  • to send publicity material (emails) about the events of Annual Biosimilars Forum, as well as about the activity of the Organizers, the events they organize and the services they provide. Such publicity material shall also provide for the appearance of such strategic partners of the Organizers that cooperate with them for the sake of providing high-quality cultural services.
  • to send marketing research and surveys

The Organizers shall not forward any personal data made available to them to any third parties, unless authorized by the express prior written consent of the data subject.

Personal and other data provided by our visitors shall not be supplemented by, or linked with, data from other sources unless we are authorized by the express prior written consent of the data subject.

REGISTRATION AND MANAGEMENT OF PERSONAL DATA

Registration and management of personal data is conducted in compliance with the provisions of Act CXII of 2011 on the right for self-determination and freedom of information and Act CXIX of 1995 on the management of name and address data for the purpose of research and direct marketing.

The registered identifiers and details of the data managed by Annual Biosimilars Forum – entered in the data protection registry maintained by the National Data Protection and Freedom of Information Authority – can be viewed on the web site of the National Data Protection and Freedom of Information Authority.

When the conditions of data storage no longer exist under the law or other legal title, Annual Biosimilars Forum deletes the recorded data from its registry. Registered Users can request from Annual Biosimilars Forum at event@accelsiors.com email addresse their data to be deleted from the registry at any time.

ADDITIONAL DATA PROTECTION INFORMATION:

Certain data and the IP address of the computers of the visitors of the Website are logged for the purpose of generating website traffic statistics and the detection of potentially occurring errors and attack attempts. Annual Biosimilars Forum does not connect the IP address to any other data that could identify the person of the visitor in any way. No other cookies or web bugs are downloaded during visiting the Web Site.

References and hyperlinks may be available on the Website that lead to web sites maintained by other service providers, where Annual Biosimilars Forum has no influence on the practice and policy related to the management of personal information. Please note that if you click on such references or hyperlinks, you will be directed to the websites of other service providers. These websites are not and cannot be under Annual Biosimilars Forum’s control; therefore the operator assumes no responsibility for the data communication and personal rights procedures of these websites. For these cases, if you wish, please read the statements related to the protection of personal data published by the service providers of these web sites.

Use of the services of the Website is considered agreement with the data management and data storage. If you have any comments regarding the above, please do not hesitate to contact the Annual Biosimilars Forum team.